The validation of epidemiologic significance in measurment of serum vaspin levels associated with metabolic syndrome

近年来，代谢综合征（MetS）作为心血管代谢疾病的病因引起了广泛关注。vaspin（内脏脂肪组织来源的丝氨酸蛋白酶抑制剂）的血清水平与基于内脏脂肪化的胰岛素抵抗相关，并且在实验动物模型中证明vaspin可能具有潜在的胰岛素增敏作用。在这项针对日本普通人群的横断面研究中，vaspin血清浓度与体重指数（BMI）、胰岛素抵抗的稳态模型评估（HOMA-IR）和B型超声检查显示的颈总动脉（IMT）内膜中层厚度呈正相关。然而，需要进一步的研究来评估预测的因果关系之间的vaspin和内脏肥胖相关的代谢紊乱的发展，并证明vaspin作为生物标志物的效用。因此，2011年的数据更正工作目前正在进行。

Recently, metabolic syndrome (MetS) has gathered the great attention as the cause of cardiometabolic diseases. Serum levels of vaspin (Visceral adipose tissue-derived serin protease inhibitor) is associated with insulin resistance based on visceral adipocity, and it was demonstrated that vaspin might have a potentially insulin-sensitizing effects in experimental animal models. In this cross sectional study for Japanese general population, vaspin serum concentrations were positively associated with body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) and intima-media thickness of common carotid artery (IMT) on B-mode ultrasonography. However, a further investigation is needed to evaluate the predicted causal relationship between vaspin and development of the visceral obesity-associated metabolic disorders, and to testify the utility of vaspin as a biomarker. Therefore, the data correction has currently been ongoing in 2011.